Patents by Inventor Thomas Pillow

Thomas Pillow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11242344
    Abstract: The present disclosure relates to bifunctional compounds, which can be used as modulators of targeted ubiquitination. In particular, the present disclosure is directed to compounds which contain on one end a VHL ligand moiety, which binds to the VHL E3 ubiquitin ligase, and on the other end a moiety that binds a target protein such that degradation of the target protein/polypeptide is effectuated. Also disclosed are VHL ligands.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: February 8, 2022
    Assignee: Genentech, Inc.
    Inventors: Nicole Blaquiere, Peter Dragovich, Lewis J. Gazzard, Thomas Pillow, Steven T. Staben, Binqing Wei, Jianfeng Xin
  • Publication number: 20210309660
    Abstract: The present disclosure relates to bifunctional compounds, which can be used as modulators of targeted ubiquitination. In particular, the present disclosure is directed to compounds which contain on one end a VHL ligand moiety, which binds to the VHL E3 ubiquitin ligase, and on the other end a moiety that binds a target protein such that degradation of the target protein/polypeptide is effectuated. Also disclosed are VHL ligands.
    Type: Application
    Filed: April 24, 2020
    Publication date: October 7, 2021
    Inventors: Nicole Blaquiere, Peter Dragovich, Lewis J. Gazzard, Thomas Pillow, Steven T. Staben, Binqing Wei, Jianfeng Xin
  • Patent number: 11135303
    Abstract: A conjugate of formula (A): where Y is selected from a single bond, and a group of formulae A1 or A2: where N shows where the group binds to the N10 of the PBD moiety; RL1 and RL2 are independently selected from H and methyl, or together with the carbon atom to which they are bound form a cyclopropylene group; CBA represents a cell binding agent; Q is independently selected from O, S and NH; R11 is either H, or R or, where Q is O, SO3M, where M is a metal cation.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: October 5, 2021
    Assignee: Medimmune Limited
    Inventors: John A. Flygare, Janet L. Gunzner-Toste, Thomas Pillow, Philip Wilson Howard, Luke Masterson
  • Patent number: 11104673
    Abstract: This invention relates to quaternary amine linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: August 31, 2021
    Assignee: Genentech, Inc.
    Inventors: John A. Flygare, Thomas Pillow, Leanna Staben
  • Publication number: 20210221821
    Abstract: The present disclosure relates to compounds and salts thereof that are useful for inhibiting target polypeptides and proteins, in particular, bromodomain (e.g., BRD4) proteins. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated diseases or disorders.
    Type: Application
    Filed: March 10, 2021
    Publication date: July 22, 2021
    Applicant: Genentech, Inc.
    Inventors: Robert Anthony BLAKE, Peter DRAGOVICH, Lewis J. GAZZARD, Susan KAUFMAN, Tracy KLEINHEINZ, Thomas PILLOW, Steven T. STABEN, Binqing WEI
  • Patent number: 10729738
    Abstract: The invention relates generally to disulfide drug conjugates wherein a linker comprising a sulfur-bearing carbon atom substituted with at least one hydrocarbyl or substituted hydrocarbyl is conjugated by a disulfide bond to a cysteine sulfur atom of a targeting carrier, and wherein the linker is further conjugated to a drug moiety. The invention further relates to activated linker-drug conjugates suitable for conjugation to a targeting carrier by a disulfide bond. The invention further relates to methods for preparing hindered disulfide drug conjugates.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: August 4, 2020
    Assignee: Genentech, Inc.
    Inventors: Peter Dragovich, Zhonghua Pei, Thomas Pillow, Jack Sadowsky, Jinhua Chen, John Wai
  • Patent number: 10730900
    Abstract: The invention relates generally to a calicheamicin molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody directly conjugated by a disulfide to one or more calicheamicin molecules.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: August 4, 2020
    Assignee: Genentech, Inc.
    Inventor: Thomas Pillow
  • Publication number: 20200222545
    Abstract: The invention relates generally to a silvestrol molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody conjugated by a linker to one or more silvestrol drug moieties and methods of treatment.
    Type: Application
    Filed: March 23, 2020
    Publication date: July 16, 2020
    Applicant: Genentech, Inc.
    Inventors: Thomas Pillow, Andrew G. Polson, Bing Zheng
  • Publication number: 20200157240
    Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof pharmaceutical compositions containing them, and to their use in therapy for the prevention treatment of cancer.
    Type: Application
    Filed: November 26, 2019
    Publication date: May 21, 2020
    Inventors: John FLYGARE, Janet GUNZNER-TOSTE, Thomas PILLOW, Brian SAFINA, Vishal VERMA, Binqing WEI, Guiling ZHAO, Leanna STABEN, Philip Wilson HOWARD, Luke MASTERSON
  • Patent number: 10639373
    Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conjugates.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: May 5, 2020
    Assignee: Genentech, Inc.
    Inventors: Peter Dragovich, Thomas Pillow, Jack Sadowsky, Mark X. Sliwkowski, BinQing Wei
  • Patent number: 10639378
    Abstract: The invention relates generally to a silvestrol molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody conjugated by a linker to one or more silvestrol drug moieties and methods of treatment.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: May 5, 2020
    Assignee: Genentech, Inc.
    Inventors: Thomas Pillow, Andrew G. Polson, Bing Zheng
  • Patent number: 10632196
    Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conjugates.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: April 28, 2020
    Assignee: Genentech, Inc.
    Inventors: Peter Dragovich, Thomas Pillow, Jack Sadowsky, Mark X. Sliwkowski, BinQing Wei
  • Publication number: 20200085965
    Abstract: The invention relates generally to pyrrolobenzodiazepine monomer and dimer prodrugs having a glutathione-activated disulfide prodrug moiety, a DT-diaphorase-activated quinone prodrug moiety or a reactive oxygen species-activated aryl boronic acid or aryl boronic ester prodrug moiety. The invention further relates to pyrrolobenzodiazepine prodrug dimer-antibody conjugates.
    Type: Application
    Filed: November 20, 2019
    Publication date: March 19, 2020
    Applicant: GENENTECH, INC.
    Inventors: Peter DRAGOVICH, Zhonghua PEI, Thomas PILLOW, Jack SADOWSKY, Vishal VERMA, Donglu ZHANG
  • Publication number: 20200087297
    Abstract: This invention relates to quaternary amine linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.
    Type: Application
    Filed: November 27, 2019
    Publication date: March 19, 2020
    Applicant: Genentech, Inc.
    Inventors: John A. Flygare, Thomas Pillow, Leanna Staben
  • Patent number: 10576164
    Abstract: Conjugate compounds of formula (A): wherein: R2 is where R36a and R36b are independently selected from H, F, C1-4 saturated alkyl, C2-3 alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C1-4 alkyl amido and C1-4 alkyl ester; or, when one of R36a and R36b is H, the other is selected from nitrile and a C1-4 alkyl ester; R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, NO2, Me3Sn and halo; R7 is independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, NO2, Me3Sn and halo; Y is selected from formulae A1, A2, A3, A4, A5 and A6: L is a linker connected to a cell binding agent; CBA is the cell binding agent; n is an integer selected in the range of 0 to 48; RA4 is a C1-6 alkylene group; either (a) R10 is H, and R11 is OH, ORA, where RA is C1-4 alkyl; or (b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R10 is H and R11 is OSOzM, wher
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: March 3, 2020
    Assignees: MedImmune Limited, Genentech, Inc.
    Inventors: Philip Wilson Howard, John A. Flygare, Thomas Pillow, Binqing Wei
  • Patent number: 10556895
    Abstract: This invention relates to quaternary amine linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: February 11, 2020
    Assignee: Genentech, Inc.
    Inventors: John A. Flygare, Thomas Pillow, Leanna Staben
  • Publication number: 20200017601
    Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody.
    Type: Application
    Filed: March 14, 2019
    Publication date: January 16, 2020
    Applicant: Genentech, Inc.
    Inventors: Sunil BHAKTA, Hans ERICKSON, Jagath R. JUNUTULA, Katherine KOZAK, Rachana OHRI, Thomas PILLOW
  • Patent number: 10533058
    Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, pharmaceutical compositions containing them, and to their use in therapy for the prevention treatment of cancer.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: January 14, 2020
    Assignees: Genentech Inc., Medimmune Limited
    Inventors: John Flygare, Janet Gunzner-Toste, Thomas Pillow, Brian Safina, Vishal Verma, Binqing Wei, Guiling Zhao, Leanna Staben, Philip Wilson Howard, Luke Masterson
  • Patent number: 10532108
    Abstract: The invention relates generally to pyrrolobenzodiazepine monomer and dimer prodrugs having a glutathione-activated disulfide prodrug moiety, a DT-diaphorase-activated quinone prodrug moiety or a reactive oxygen species-activated aryl boronic acid or aryl boronic ester prodrug moiety. The invention further relates to pyrrolobenzodiazepine prodrug dimer-antibody conjugates.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: January 14, 2020
    Assignee: GENENTECH, INC.
    Inventors: Peter Dragovich, Zhonghua Pei, Thomas Pillow, Jack Sadowsky, Vishal Verma, Donglu Zhang
  • Patent number: 10442836
    Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a 1-(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimer drug moiety via a linker, and methods of using the antibody-drug conjugates.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: October 15, 2019
    Assignee: Genentech, Inc.
    Inventors: John Flygare, Thomas Pillow, Brian Safina, Vishal Verma, Binqing Wei, William Denny, Anna Giddens, Ho Lee, Guo-Liang Lu, Christian Miller, Gordon Rewcastle, Moana Tercel, Muriel Bonnet